Friday, 16 October 2026European Markets

HDF Stock Was Up By 15.17% Before The Weekend

Loading stream...

(vianews) - the market ended the session with hdf (hdf.pa) jumping 15.17% to €7.06 on friday, after two consecutive sessions in a row of gains. cac 40 rose 0.01% to €8,205.81, after three consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

hdf's last close was €7.06, 71.87% below its 52-week high of €25.10.

about hdf

hydrogène de france société anonyme develops and operates as independent power producer in france and internationally. it operates two hydrogen power plants; and manufactures and sells high power fuel cells. the company was incorporated in 2012 and is based in lormont, france.

earnings per share

as for profitability, hdf has a trailing twelve months eps of €-0.24.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.11%.

yearly top and bottom value

hdf's stock is valued at €7.06 at 21:33 est, way under its 52-week low of €11.26.

moving average

hdf's worth is way below its 50-day moving average of €14.80 and way below its 200-day moving average of €16.92.

volatility

hdf's last week, last month's, and last quarter's current intraday variation average was a positive 2.94%, a negative 0.44%, and a positive 2.30%.

hdf's highest amplitude of average volatility was 4.81% (last week), 2.09% (last month), and 2.30% (last quarter).

more news about hdf (hdf.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com